How should immune checkpoint inhibitors be managed during the COVID-19 pandemic?

How can you maintain the health of your skin while protecting yourself from COVID-19?

Answers to questions frequently asked by cancer patients treated by immunotherapy during Covid-19

PROMOTING THE DEVELOPMENT AND


ACCESS TO IMMUNOTHERAPIES IN FRANCE

The FITC represents oncologists and research scientists involved in understanding tumor immunity and developing cancer immunotherapies in collaboration with French academic societies (SFI, SFC, LySA etc.).

Our objective is to bridge national institutions (HAS, CEPS, INCa, etc. ) and governing bodies (Senate, National assembly) in order to improve the implementation of immunotherapies in France and to increase funding of research in cancer immunology.

For complete transparency in access to immunotherapy, you will discover soon the list of cancers for which treatment by immunotherapy is covered by social healthcare in France.

Discover soon the list of clinical trials in cancer immunotherapy currently open in France.

INTERNATIONAL COLLABORATION

AND NETWORKING

The FITC is part of the World Immunotherapy Council (WIC) – a group of societies across the globe, dedicated to the development of immunotherapy and immuno-oncology.

OUR ANNUAL MEETING

The French Society of Immunotherapy’s (FITC) annual meeting brings together several stakeholders – scientists, clinicians, pharmacists, ethic committees, regulatory agencies – around a high caliber scientific event centered on advances in the field of cancer immunology and immunotherapy. We also organize scientific updates and discussions over data presented at main cancer conferences such as AACR, ASCO, ASH, EHA, ESMO and SITC.

In particular, young scientists in France are offered a chance to present their work in clinical, fundamental and translational immuno-oncology.

PATIENT AND FAMILY EDUCATION

The FITC considers it a priority to educate patients and their families about the immunology of cancer and the therapy they receive. A freely available document introduces patients to the basic mechanisms of immunology, treatment by immunotherapy and the management of potential side-effects. We aim to constantly supplement these guidelines as new strategies are developed.

PROMOTING RESEARCH

The FITC has created the first directory of French clinical and basic science research teams working towards understanding tumor immunology and immunotherapy. The expertise of each team is described to increase collaboration between clinicians, scientists and industrial partners.

An FITC scientific council provides expert advice to evaluate documents required by French institutions and partners.

A collaboration initiated between French research groups aims to build an immunology Atlas of human tumors.

IMPROVE TRAINING

The FITC has catalogued French training programs in cancer immunology and immunotherapy. FITC-endorsed courses can be found here.

Courses specific to the FITC are also available in the form of short videos on specific themes (research and clinic) and are associated with a discussion forum.

A training workshop is offered each year during the annual meeting.

BRINGING PATIENTS TOGETHER

AROUND IMMUNOTHERAPY

We believe that patients should be able to influence decisions pertaining to their access to immunotherapy. The FITC unites patient support groups for different cancers around immunotherapy.

We aim to provide information and explanations regarding French regulatory constraints to enable patient groups to comprehend the processes and ensure their voice is heard.

become a member

To become a member of the FITC, register here.

FITC NEWS

To subscribe to the FITC newsletter, register here.